Recurrent HR+ Breast Cancer
Recurrent HR+ Breast Cancer
A 58-Year-Old Woman With Recurrent HR+ Breast Cancer
December 2013
- A 58-year-old postmenopausal woman was referred for further evaluation of a suspicious left-sided lesion found incidentally on routine mammogram
- MRI revealed a 4.3-cm lesion in her left breast
- PMH unremarkable
- She underwent lumpectomy with axillary staging
- Biopsy findings:
- Histology: lobular carcinoma, grade 2
- Hormone receptor status: ER+/ PR (-)
- HER2,IHC 1+
- OncotypeDx RS, 19
- Staging, T2N0M0
- ECOG 0
- She was started on adjuvant anastrozole
September 2018
- On routine follow-up, the patient reports increasing fatigue and intermittent bouts of abdominal pain with nausea
- CT with contrast showed several small lesions in the liver; biopsy confirmed metastatic disease.
- The patient was started on ribociclib; anastrozole was changed to fulvestrant
- Imaging at 3 and 6 months showed a partial response
Recent Videos
Related Content
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024Article
During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020Podcast
In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
